engleski

Concept of HRPC conversion into a chronic disease

One half of the patients with hormone refractory prostate cancer referred to docetaxel/ estm therapy are converted to androgen hypesensitive disease that does not exert osteolysis and is thus less risky disease. This conversion is probably attributed to androgen receptor amplification.

HRPC; cytotoxic therapy; docetaxel plus estm; conversion of hormone refractory to hormone hypersensitive disease

nije evidentirano